Navigation Links
Jennerex Announces First Patient Treated in Phase 2a Clinical Trial of JX-594 as a Neoadjuvant Therapy in Colorectal Cancer Patients Undergoing Surgery
Date:12/21/2011

SAN FRANCISCO, Dec. 21, 2011 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, today announced that the first patient has been treated in a Phase 2a clinical trial of JX-594 as a neoadjuvant therapy in patients who are undergoing surgery to treat colorectal cancer that has spread to the liver.

The study is being led by Rebecca Auer, M.D., surgical oncologist at The Ottawa Hospital, associate scientist at the Ottawa Hospital Research Institute and assistant professor of surgery at the University of Ottawa in Ottawa, Canada.  The clinical trial is being supported by funding from the Ontario Institute for Cancer Research­.

"This trial will allow us to evaluate the use of JX-594 in patients with surgically resectable disease, potentially expanding the role of this therapy in the treatment continuum," said David H. Kirn, M.D., president and chief medical officer of Jennerex.  "We continue to believe that JX-594 could play an integral role in the treatment of cancers and look forward to the results of this trial along with data from the larger Phase 2b study, called TRAVERSE, that is under way in patients with advanced hepatocellular carcinoma."

"In addition, this study will allow us to expand our analysis of the multi-mechanistic therapeutic activity of JX-594 through the examination of tumor specimens collected during surgery following JX-594 administration," said John C. Bell, Ph.D., senior scientist, cancer therapeutics, Ottawa Hospital Research Institute, and professor of medicine, University of Ottawa.  Dr. Bell is also the program leader of the Ontario Institute for Cancer Research's Immuno- and Bio-therapies Program.

This Phase 2a clinical trial will enroll approximately 20 patients with colorectal cancer metastases to the liver. Patients will receive a single
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
2. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
3. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
4. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
5. Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer
6. Jennerex Therapeutic Research Collaboration With Ottawa Hospital Research Institute Selected for $10 Million Grant From Ontario Institute for Cancer Research
7. Jennerex, Inc. Receives EMEA Orphan Drug Designation for JX-594 for the Treatment of Hepatocellular Carcinoma
8. Jennerex Announces Presentations at Upcoming Conferences
9. Jennerex Appoints Gregory W. Schafer as Chief Financial Officer
10. Jennerex Appoints Lara Longpre to Chief Operating Officer
11. Jennerex Names Dr. Mark P. Backer as Senior Vice President of Technical Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... HILDEN , Deutschland, und ... , ... ermöglicht QIAGEN die Entwicklung von ... Genpanels, für Blutkrebs  Neuer Test ... Patienten mit Knochenmarkserkrankungen (myelodysplastischen Syndromen) einen günstigen ...
(Date:7/24/2014)... July 24, 2014  Uroplasty, Inc. (NASDAQ: ... manufactures and markets innovative proprietary products to treat ... fiscal 2015 first quarter ended June 30, 2014.  ...  PC Neuromodulation System grew 19% to $4.1 million, ... quarter of the prior year.  Total revenue for ...
(Date:7/24/2014)... July 24, 2014  Mettler-Toledo International Inc. (NYSE: ... 2014.  Provided below are the highlights: , ... quarter compared with the prior year. Reported sales increased ... , Net earnings per diluted share as reported (EPS) ... of 2013. Adjusted EPS was $2.57, an increase of ...
Breaking Medicine Technology:QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5Uroplasty Reports Fiscal First Quarter Results 2Uroplasty Reports Fiscal First Quarter Results 3Uroplasty Reports Fiscal First Quarter Results 4Uroplasty Reports Fiscal First Quarter Results 5Uroplasty Reports Fiscal First Quarter Results 6Uroplasty Reports Fiscal First Quarter Results 7Uroplasty Reports Fiscal First Quarter Results 8Uroplasty Reports Fiscal First Quarter Results 9Uroplasty Reports Fiscal First Quarter Results 10Uroplasty Reports Fiscal First Quarter Results 11Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 14
... , SAN DIEGO , Feb. 3 ... BDX ), today announced the launch of the ... prevention of influenza. Recognizing that schools and hospitals are important centers ... is designed to communicate that everyone can help prevent the spread ...
... , ATLANTA , Feb. 3 ... of Vytex® Natural Rubber Latex (NRL), a patented, all-natural ... natural rubber latex, has engaged The Investor Relations Group ... New York City , to serve as its ...
Cached Medicine Technology:BD Launches 'Be a Flu Fighter' Campaign to Promote Influenza Awareness and Prevention in Schools, Hospitals and Laboratories 2Vystar Corporation Engages The Investor Relations Group 2Vystar Corporation Engages The Investor Relations Group 3
(Date:7/25/2014)... The North America Artificial lift market report defines ... analysis and forecast of revenue. The artificial lift market in ... in 2013 to around $7 billion by 2018, at a ... through the TOC of North America artificial lift market report, ... provides a glimpse of the segmentation in North America Artificial ...
(Date:7/25/2014)... July 25, 2014 Agoura Hills dentist ... on Zoom Whitening. Zoom Whitening is one of the most ... through a dental professional. This light-assisted treatment uses a prescription-strength ... of the tooth to break up stains that are in ... coffee, tea, wine, soft drink and tobacco stains. , ...
(Date:7/25/2014)... The rising pharmaceutical sale across the US ... of the US PBM industry. A slow but steady increase ... sales in the US over the past few years. The ... in the prescription volume over the past few years. , ... 2013 Edition” the demand for the pharmacy benefit managers in ...
(Date:7/25/2014)... July 25, 2014 Ross A. Clevens, ... been invited to join the exclusive Obagi Clinical Advisory ... facial plastic surgeons, plastic surgeons and dermatologists. , ... exclusive Advisory Board of thought leaders held its first ... meeting was to give Obagi the opportunity to meet ...
(Date:7/25/2014)... 25, 2014 (HealthDay News) -- Dietary changes can dramatically ... a daily basis, according to a new study. ... might help detect and ease flare-ups for people with ... colitis and Crohn,s disease), the researchers said. Trillions ... effect on human health isn,t well understood, the Massachusetts ...
Breaking Medicine News(10 mins):Health News:North America Artificial Lift Services Market is Expected to Reach $7 Billion in 2018 - New Report by MicroMarket Monitor 2Health News:North America Artificial Lift Services Market is Expected to Reach $7 Billion in 2018 - New Report by MicroMarket Monitor 3Health News:North America Artificial Lift Services Market is Expected to Reach $7 Billion in 2018 - New Report by MicroMarket Monitor 4Health News:Agoura Hills Dentist, Dr. Amir Choroomi, is Now Offering a Promotion on Zoom Whitening 2Health News:US Pharmacy Benefit Management (PBM) Market Trends and Developments Now Available at MarketReportsOnline.com 2Health News:US Pharmacy Benefit Management (PBM) Market Trends and Developments Now Available at MarketReportsOnline.com 3Health News:Renowned Melbourne Plastic Surgeon to Join Private Medical Advisory Board 2Health News:Diet Changes Can Alter Gut Bacteria, Study Says 2
... MONDAY, March 7 (HealthDay News) -- Genetics may predispose some ... and stress are a fact of daily life -- to ... warns. The culprit is a specific abnormality of the ... gene is known to play a key role in the ...
... March 7, 2011 Embargoed by the journal ... time Working as part of a public program to ... useful molecules, scientists from The Scripps Research Institute and ... potent class of potential anti-cancer and anti-neurodegenerative disorder compounds. ...
... it won,t be obvious to UCSF Medical Center patients, behind ... processes their medications. With a new automated hospital pharmacy, believed ... technology and electronics to prepare and track medications with the ... error has occurred in the 350,000 doses of medication prepared ...
... of recognizing tumor growth, and naturally mounts an anti-cancer ... (antigens) and present them to T cells, and those ... kill tumor cells. In recent years, researchers have attempted ... new therapies- namely, by generating a pool of tumor ...
... Transplanting stem cells derived from umbilical ... offer future therapeutic benefit for those suffering from ... says a team of neuroscience researchers from the ... Brain Repair and collaborators from three private-sector research ...
... Reinberg HealthDay Reporter , SUNDAY, March 6 (HealthDay ... a safe way to detect Down syndrome during pregnancy, researchers ... identified a gene mutation associated with Down syndrome with 100 ... is a common birth defect, with one Down syndrome birth ...
Cached Medicine News:Health News:Mix of Genetics and Stress Can Impair Mental Abilities 2Health News:Scripps Research and MIT scientists discover class of potent anti-cancer compounds 2Health News:Scripps Research and MIT scientists discover class of potent anti-cancer compounds 3Health News:Scripps Research and MIT scientists discover class of potent anti-cancer compounds 4Health News:New UCSF robotic pharmacy aims to improve patient safety 2Health News:New UCSF robotic pharmacy aims to improve patient safety 3Health News:Transplanting umbilical cord and menstrual blood-derived stem cells offer hope for disorders 2Health News:Transplanting umbilical cord and menstrual blood-derived stem cells offer hope for disorders 3Health News:Transplanting umbilical cord and menstrual blood-derived stem cells offer hope for disorders 4Health News:Noninvasive Test May Identify Down Syndrome Early On 2
... RayShield X-Drape combines full 0.25 ... Soft Fiber sterile drape material that ... sterile field between the clinician and ... when the clinician must be in ...
... The first mobile clinical assistant that ... convergence of technologies in the C5 ... normally do during your,shift such as ... take pictures using one single device.,With ...
Patent Pending lateral flow assay platform that contributes to increased sensitivty...
Colloidal Gold Conjugated, Rabbit anti-goat IgG (H&L) - 50 OD...
Medicine Products: